Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phytomenadione for Coronary Artery Calcification in Hemodialysis Patients
NCT04247087Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial of phytomenadione in Coronary artery calcification (CAC) (2 arms), sponsored by Instituto Mexicano del Seguro Social. Primary endpoint: Coronary Calcium Score at 12 months. Started Sep 2017; status: completed.
02
Drugs
phytomenadione
03
Conditions
Coronary artery calcification (CAC)
Beyond the preview
Go deeper on NCT04247087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247087.